Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03854227 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03854227 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 54 participants.
The verdict
NCT03854227, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Interventions
- DRUG PF-06939999 dose escalation
- DRUG PF-06939999 monotherapy
- DRUG PF-06939999 in combination with docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-14 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03854227
The ClinicalTrials.gov registry entry for NCT03854227 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06939999 dose escalation is the first listed.
NCT03854227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03854227 about?
NCT03854227 is a clinical study titled "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors". This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
What is the current status of trial NCT03854227?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-03-14. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03854227?
The interventions under investigation include: PF-06939999 dose escalation (DRUG), PF-06939999 monotherapy (DRUG), PF-06939999 in combination with docetaxel (DRUG).
Who is sponsoring clinical trial NCT03854227?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.